Appili Therapeutics develops targeted anti-infective therapies, including a novel oral suspension for serious anaerobic infections and a live-attenuated vaccine for tularemia, addressing critical gaps in treatment options for infectious diseases. The company focuses on accelerating drug development and commercialization to meet unmet patient needs in both infectious disease and biodefense.
Funding
$292.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for anaerobic and protozoal infections often involve tablets with a bitter taste, leading to poor patient compliance, especially among elderly patients or those with difficulty swallowing. Additionally, the threat of tularemia, a Category A pathogen, necessitates the development of effective vaccines for biodefense.
Solution
Appili Therapeutics develops and commercializes anti-infective therapies to address unmet needs in infectious disease and biodefense. Their lead product, LIKMEZ™, is an FDA-approved, taste-masked oral suspension of metronidazole designed to improve patient adherence in treating anaerobic and protozoal infections. Appili is also developing ATI-1701, a live-attenuated vaccine for tularemia, with the potential to provide 100% protection against aerosolized weapons-grade *Francisella tularensis*, outperforming existing vaccines in preclinical studies. The company focuses on advancing its pipeline through strategic partnerships and in-licensing to deliver solutions for patients, doctors, and society.
Target Audience
The primary target audience includes patients with anaerobic and protozoal infections, government agencies and organizations involved in biodefense, and healthcare providers seeking improved treatment options for infectious diseases.
Features
- LIKMEZ™ (ATI-1501): Taste-masked oral suspension of metronidazole for improved patient compliance
- LIKMEZ™ is the only liquid oral suspension of metronidazole approved in the U.S.
- ATI-1701: Live-attenuated vaccine for tularemia ( *F. tularensis* SCHU S4 Δ *clpB*)
- ATI-1701 demonstrated 100% protection against aerosolized weapons-grade *F. tularensis* in preclinical studies
- ATI-1701 is being developed under FDA's Animal Rule, potentially shortening the time to market approval
- ATI-1801: Novel topical antiparasitic product to treat disfiguring skin infections